Home Drug plan management

Keyword: Drug plan management

417 results found

With Canada’s public and private drug market an ever-evolving landscape, what value can be gained from collaboration and innovative solutions to ensure patient access to new medicines and vaccines in the future? During Innovative Medicines Canada’s virtual policy summit in June, Declan Hamill, vice-president of policy, regulatory and legal affairs, said the organization appreciates the […]

The growing use of specialty medications among plan members continued to drive the increase in plan sponsors’ drug plan costs last year, well eclipsing the increase in traditional drug spending, according to Telus Health. Canadian plan sponsors’ drug spending on insured plan members between the ages of 25 and 64 increased 3.6 per cent in […]

While the rates of drug and disability claims are returning to their pre-pandemic levels, employers are still contending with the impact of the coronavirus crisis on their benefits plans. Following the declaration of the pandemic in March 2020, there was a subsequent surge in drug claims attributed to medication stockpiling, said Frédéric Leblanc, strategic advisor […]

On April 15, Benefits Canada hosted 2021 Tech Insights: Spring Edition, an event designed to showcase the latest technology in benefits, administration and plan member offerings. This event specifically provides a forum for companies to sell you on the benefits of their technology. You can view the conference highlights below: The benefits of digital pharmacy for plan […]

Last February, Carolyne Eagan’s mother was suddenly stricken with an excruciatingly painful condition called trigeminal neuralgia, which prevented her from eating, talking or drinking without triggering a flare of pain in her head. Eagan gathered up her mom’s medications and got into the ambulance with her, feeling increasingly distressed as she wasn’t able to answer […]

Copyright_Wavebreak Media Ltd_123RF

“What if I told you at least one in four members of your benefits plan has an unresolved health risk?” asked Radpay, the president of HumanisRx, during Benefits Canada‘s 2021 Tech Insights: Spring Edition conference. In a study in partnership with Munich Re, HumanisRx reviewed the insurer’s claims history experience for 85,000 plan members and […]

Copyright_Mikhail Tsikhanovich_123RF

The New Brunswick government is expanding the use of biosimilars for certain chronic conditions in its public drug plans. Approximately 3,000 beneficiaries of the province’s drug plans who are living with diseases such as inflammatory arthritis, inflammatory bowel disease, diabetes and psoriasis will have until Nov. 30 to switch from a biologic to the biosimilar […]

  • By: Staff
  • April 23, 2021 April 26, 2021
  • 15:00
Copyright_Wavebreak Media Ltd_123RF

While a national pharmacare program is yet to be revealed by the federal government, any future plan should contain provisions for all costly treatments and not just rare diseases, says Jennifer Schmidt, a principal at Mercer Canada. Read: Federal budget highlights national childcare system, extension of pandemic subsidies This week’s federal budget announcement contained only […]

Copyright_Aleksandr Kalugin_123RF

While drug plan costs are increasing for plan sponsors, the causes for these increases may depend on which part of Canada a plan sponsor resides in, says Philippe Laplante, a principal responsible for the group benefits practice in Eckler Ltd.’s Montreal office. Over the past three years in Quebec, the average annual increase of recommended pricing […]

Growth in chronic disease and increased drug claims are two of the key factors driving up the cost of private health benefit plans, according to a new report by Innovative Medicines Canada. It found that chronic diseases accounted for 68 per cent of drug plan claims costs and 79 per cent of growth. Claims costs […]

  • By: Staff
  • January 15, 2021 April 14, 2021
  • 15:00